Evidence map›Paper›PMID 36826025›Full record

ArticleCurrent issues in molecular biology2023

Loss of Nf1 and Ink4a/Arf Are Associated with Sex-Dependent Growth Differences in a Mouse Model of Embryonal Rhabdomyosarcoma.

Wade R Gutierrez, Jeffrey D Rytlewski, Amanda Scherer, Grace A Roughton, Nina C Carnevale, Krisha Y Vyas, Gavin R McGivney, Qierra R Brockman, Vickie Knepper-Adrian, Rebecca D Dodd

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecules at Play in Cancer.Current issues in molecular biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wade R GutierrezCancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-0643-3566
Jeffrey D RytlewskiDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Amanda SchererHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Grace A RoughtonDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Nina C CarnevaleDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Krisha Y VyasDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Gavin R McGivneyCancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.
Qierra R BrockmanHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Vickie Knepper-AdrianDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Rebecca D DoddCancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-7295-1882
University of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9M
PROGRAM IN HEMOSTASIS AND THROMBOSIS FOR ACADEMICT32HL007344 · NHLBI · UNIVERSITY OF IOWA · PI Anil Kumar Chauhan, Steven R Lentz · 1985 to 2026
$6.5M
Medical Scientist Training ProgramT32GM139776 · NIGMS · UNIVERSITY OF IOWA · PI Gordon F Buchanan · 2021 to 2026
$6.4M
Predoctoral Training in the Pharmacological SciencesT32GM067795 · NIGMS · UNIVERSITY OF IOWA · PI STRACK, STEFAN · 2004 to 2021
$3.4M
NCI NIH HHS P30 CA086862NHLBI NIH HHS T32 HL007344NIGMS NIH HHS T32 GM007337NIGMS NIH HHS T32 GM067795NIGMS NIH HHS T32 GM139776NIH HHS T32 GM007337NIH HHS T32 GM067795
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS) is an aggressive form of cancer that accounts for half of all pediatric soft tissue sarcomas. Little progress has been made in improving survival outcomes over the past three decades. Mouse models of rhabdomyosarcoma are a critical component of translational research aimed at understanding tumor biology and developing new, improved therapies. Though several models exist, many common mutations found in human rhabdomyosarcoma tumors remain unmodeled and understudied. This study describes a new model of embryonal rhabdomyosarcoma driven by the loss of Nf1 and Ink4a/Arf, two mutations commonly found in patient tumors. We find that this new model is histologically similar to other previously-published rhabdomyosarcoma models, although it substantially differs in the time required for tumor onset and in tumor growth kinetics. We also observe unique sex-dependent phenotypes in both primary and newly-developed orthotopic syngeneic allograft tumors that are not present in previous models. Using in vitro and in vivo studies, we examined the response to vincristine, a component of the standard-of-care chemotherapy for RMS. The findings from this study provide valuable insight into a new mouse model of rhabdomyosarcoma that addresses an ongoing need for patient-relevant animal models to further translational research.

Indexed as

cancerInk4a/Arfmouse modelNf1rhabdomyosarcomasarcomavincristine

Identifiers

PMID36826025
PMCPMC9955904
OpenAlexW4319792034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.